These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16448574)

  • 1. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
    Chavez-Blanco A; Perez-Plasencia C; Perez-Cardenas E; Carrasco-Legleu C; Rangel-Lopez E; Segura-Pacheco B; Taja-Chayeb L; Trejo-Becerril C; Gonzalez-Fierro A; Candelaria M; Cabrera G; Duenas-Gonzalez A
    Cancer Cell Int; 2006 Jan; 6():2. PubMed ID: 16448574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells.
    Pérez-Cárdenas E; Taja-Chayeb L; Trejo-Becerril C; Chanona-Vilchis J; Chávez-Blanco A; Domínguez-Gómez G; Langley E; García-Carrancá A; Dueñas-González A
    Onco Targets Ther; 2018; 11():8823-8833. PubMed ID: 30584338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
    Mani E; Medina LA; Isaac-Olivé K; Dueñas-González A
    Eur J Gynaecol Oncol; 2014; 35(2):140-2. PubMed ID: 24772915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
    de la Cruz-Hernández E; Pérez-Cárdenas E; Contreras-Paredes A; Cantú D; Mohar A; Lizano M; Dueñas-González A
    Virol J; 2007 Feb; 4():18. PubMed ID: 17324262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.
    Mora-García Mde L; Duenas-González A; Hernández-Montes J; De la Cruz-Hernández E; Pérez-Cárdenas E; Weiss-Steider B; Santiago-Osorio E; Ortíz-Navarrete VF; Rosales VH; Cantú D; Lizano-Soberón M; Rojo-Aguilar MP; Monroy-García A
    J Transl Med; 2006 Dec; 4():55. PubMed ID: 17192185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
    Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N
    Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
    Dueñas-Gonzalez A; Coronel J; Cetina L; González-Fierro A; Chavez-Blanco A; Taja-Chayeb L
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1433-44. PubMed ID: 25154405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy.
    Segura-Pacheco B; Trejo-Becerril C; Perez-Cardenas E; Taja-Chayeb L; Mariscal I; Chavez A; Acuña C; Salazar AM; Lizano M; Dueñas-Gonzalez A
    Clin Cancer Res; 2003 May; 9(5):1596-603. PubMed ID: 12738711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
    Candelaria M; Gallardo-Rincón D; Arce C; Cetina L; Aguilar-Ponce JL; Arrieta O; González-Fierro A; Chávez-Blanco A; de la Cruz-Hernández E; Camargo MF; Trejo-Becerril C; Pérez-Cárdenas E; Pérez-Plasencia C; Taja-Chayeb L; Wegman-Ostrosky T; Revilla-Vazquez A; Dueñas-González A
    Ann Oncol; 2007 Sep; 18(9):1529-38. PubMed ID: 17761710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.
    Bauman J; Shaheen M; Verschraegen CF; Belinsky SA; Houman Fekrazad M; Lee FC; Rabinowitz I; Ravindranathan M; Jones DV
    Transl Oncol; 2014 Apr; 7(3):349-54. PubMed ID: 24746712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
    Arce C; Pérez-Plasencia C; González-Fierro A; de la Cruz-Hernández E; Revilla-Vázquez A; Chávez-Blanco A; Trejo-Becerril C; Pérez-Cárdenas E; Taja-Chayeb L; Bargallo E; Villarreal P; Ramírez T; Vela T; Candelaria M; Camargo MF; Robles E; Dueñas-González A
    PLoS One; 2006 Dec; 1(1):e98. PubMed ID: 17183730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression.
    Song Y; Zhang C
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):605-13. PubMed ID: 18521605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Hydralazine on demethylation status and expression of APC gene, proliferation and apoptosis of human cervical cancer cell lines].
    Song YH; Zhang CJ
    Zhonghua Bing Li Xue Za Zhi; 2007 Sep; 36(9):614-8. PubMed ID: 18070451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines.
    Pacheco MB; Camilo V; Lopes N; Moreira-Silva F; Correia MP; Henrique R; Jerónimo C
    Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
    De la Cruz-Hernández E; Perez-Plasencia C; Pérez-Cardenas E; Gonzalez-Fierro A; Trejo-Becerril C; Chávez-Blanco A; Taja-Chayeb L; Vidal S; Gutiérrez O; Dominguez GI; Trujillo JE; Duenas-González A
    Oncol Rep; 2011 Feb; 25(2):399-407. PubMed ID: 21152880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
    Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
    Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic effects of valproic acid and mitomycin C in adenocarcinoma cell lines and fresh tumor cells of patients with colon cancer.
    Friedmann I; Atmaca A; Chow KU; Jäger E; Weidmann E
    J Chemother; 2006 Aug; 18(4):415-20. PubMed ID: 17024798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
    Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
    Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models.
    Igarashi K; Yamamoto N; Hayashi K; Takeuchi A; Kimura H; Miwa S; Hoffman RM; Tsuchiya H
    Anticancer Res; 2016 Sep; 36(9):4477-82. PubMed ID: 27630284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.